Pyonephrosis medical therapy

Jump to navigation Jump to search

Pyonephrosis Microchapters

Home

Patient Information

Overview

Pathophysiology

Causes

Epidemiology and Demographics

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Pyonephrosis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Pyonephrosis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Pyonephrosis medical therapy

CDC on Pyonephrosis medical therapy

Pyonephrosis medical therapy in the news

Blogs on Pyonephrosis medical therapy

Directions to Hospitals Treating Pyonephrosis

Risk calculators and risk factors for Pyonephrosis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Harsh Vardhan Chawla, M.B.B.S.[2]

Medical therapy

  • Pyonephrosis is a urological emergency.
  • Hemodynamically unstable patients may require aggressive fluid resuscitation with crystalloids and pressor agent (dopamine) to maintain adequate blood pressure.
  • Before initiating antimicrobial treatment for suspected pyonephrosis, a urine and blood culture and susceptibility test should always be performed.
  • All patients with pyonephrosis should be empirically treated with long-acting, broad spectrum antibiotics which may be later narrowed based on culture report.
  • Presence of pyonephrosis and obstruction reduces the efficacy and penetration of antibiotics. Therefore, drainage of the pus should be done immediately after administering the antibiotics.
  • Intravenous Ampicillin + Gentamicin is a good initial option which covers both gram positive and negative organisms.
  • Anaerobic coverage with Clindamycin, antifungal or antitubercular agents may be required depending upon the clinical scenario.
  • Carbapenem-resistant enterobacteriaceae can be treated with ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam, imipenem-cilastatin-relebactam, plazomicin, eravacycline, and cefiderocol.

References

Template:WH Template:WS